deltatrials
Completed PHASE3 NCT00406588

SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of SLV308 as Adjunct Therapy to Levodopa in Patients With Parkinson's Disease Experiencing Motor Fluctuations.

Sponsor: Solvay Pharmaceuticals

Conditions Advanced Stage Parkinson's Disease
Interventions Levodopa (Pardoprunox) Placebo Comparator
Updated 8 times since 2017 Last updated: Feb 9, 2015 Started: Mar 31, 2007 Primary completion: Apr 30, 2008 Completion: May 31, 2008

A PHASE3 clinical study on Advanced Stage Parkinson's Disease, this trial is completed. The trial is conducted by Solvay Pharmaceuticals and has accumulated 8 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE3

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Solvay Pharmaceuticals
Data source: Solvay Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alto da Glória, Brazil, Augusta, United States, Bellavista Callao, Peru, Belo Horizonte, Brazil, Birmingham, United States, Bogotá, Colombia, Buenos Aires, Argentina, Calgary, Canada, Campinas, Brazil, Chicago, United States and 50 more location s